000788，董事长被批准逮捕！涉嫌刑事犯罪

Core Viewpoint - The recent developments regarding the chairman of Beijing University Pharmaceutical (北大医药) indicate significant legal issues, with the chairman being arrested for criminal charges, yet the company's operations and control remain stable [1][2]. Group 1: Company Leadership and Governance - On November 12, Beijing University Pharmaceutical announced that its chairman and president, Xu Xiren, has been arrested for criminal charges, with the board functioning normally under the temporary leadership of authorized directors [1]. - Prior to the arrest, on October 25, the company had already announced Xu's temporary inability to perform his duties, delegating responsibilities to other board members [1]. - The company confirmed that its control structure has not changed and that its financial and operational management remains stable [2]. Group 2: Company Background and Operations - Beijing University Pharmaceutical, originally established in 1965, was listed on the Shenzhen Stock Exchange in 1997 and has undergone several changes in control, with the current actual controller being Xu Xiren [2][3]. - The company specializes in drug research, production, and sales, focusing on key areas such as anti-infection, analgesics, mental health, and chronic diseases, with a total of 166 drug approvals and 13 first-generic drug approvals [2]. - The company has developed a comprehensive pharmaceutical sales network across China, covering drug sales, medical circulation, hospital procurement, and supply chain management [2]. Group 3: Recent Performance Metrics - For the first three quarters of 2025, Beijing University Pharmaceutical reported a revenue of 1.231 billion yuan, a year-on-year decrease of 19.76%, while net profit increased by 4.31% to 136 million yuan [3].